Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback

Core Insights - Gossamer Bio Inc. is identified as a penny stock with the potential for significant price appreciation, specifically a rise of 1000 percent [1] - The company faced a setback in its Phase 3 PROSERA study for seralutinib in pulmonary arterial hypertension, missing its primary endpoint, but plans to discuss future steps with the FDA [1] - Analysts from Oppenheimer and H.C. Wainwright maintain bullish ratings despite lowering their price targets, indicating strong upside potential based on current share prices [2] Analyst Ratings - Oppenheimer has maintained an Outperform rating while reducing its price target from $12 to $3, suggesting an upside of over 700% from the current share price of approximately $0.37 [2] - H.C. Wainwright has kept its Buy rating and lowered its target from $10 to $5, implying an upside of more than 1,200% [2] Probability of Success - Analyst Patrick Trucchio from H.C. Wainwright has reduced the estimated probability of success for seralutinib in PAH from 70% to 50%, yet still sees evidence of clinical activity in heavily pretreated patients [3] - There is a belief that a potential path forward for the drug may still exist, although regulatory and capital uncertainties are expected to persist [3] Company Overview - Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary hypertension and other serious diseases [4]